Obsidian’s CAR controls

Obsidian Therapeutics Inc. had no trouble attracting investors to its $49.5 million in series A round after it generated a preclinical pipeline of CAR T therapies with tunable activity.

GV led the round and was joined by fellow new investors Takeda Ventures Inc., Vertex Ventures HC, Amgen Ventures and ShangPharma Investment Group. Existing investors Atlas Venture and Alexandria Venture Investments also participated. ...